Latest Ratios: P/E Ratio -2.2x · EV/EBITDA N/A · ROE -302.4%. (2008–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $27M | $67M | $198M | $339M | $784M | $131M | $112M | $119M | $96M | $119M | $3.4B |
| Enterprise Value | $28M | $68M | $192M | $318M | $756M | $136M | $118M | $120M | $96M | $117M | $3.4B |
| P/E Ratio → | -2.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.49 | 41.31 | 121.73 | 225.50 | 551.59 | 104.78 | 79.60 | 84.30 | 147.21 | 259.73 | 5261.84 |
| P/B Ratio | — | — | 23.95 | 15.60 | 19.46 | 49.65 | 10.00 | 2225.40 | 35.81 | 128.36 | 837.19 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 42.17 | 118.04 | 210.96 | 532.35 | 108.93 | 83.74 | 85.34 | 146.04 | 255.87 | 5254.42 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.1% | 49.1% | 62.6% | 66.4% | 65.7% | 64.3% | 62.3% | 70.5% | 77.4% | 60.2% | 53.5% |
| Operating Margin | -673.7% | -673.7% | -744.5% | -1729.3% | -1437.9% | -2025.1% | -1604.2% | -556.9% | -1183.0% | -1429.6% | -672.4% |
| Net Profit Margin | -751.4% | -751.4% | -859.1% | -1709.6% | -1383.6% | -2067.0% | -1373.7% | -714.5% | -1183.0% | -1429.6% | -732.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -302.4% | -302.4% | -93.1% | -83.0% | -91.6% | -373.1% | -343.7% | -734.8% | -428.5% | -259.2% | -116.5% |
| ROA | -125.9% | -125.9% | -69.7% | -74.1% | -69.2% | -146.1% | -148.7% | -275.1% | -240.9% | -154.6% | -146.6% |
| ROIC | -473.8% | -473.8% | -847.8% | -304.7% | -147.5% | -152.7% | -182.7% | -341.6% | -1070.6% | — | — |
| ROCE | -184.7% | -184.7% | -75.0% | -83.5% | -92.3% | -333.1% | -391.9% | -572.7% | -394.7% | -244.1% | -107.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.33 | 0.01 | 0.02 | 2.22 | 0.53 | 30.58 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.73 | -1.01 | -0.68 | 1.97 | 0.52 | 27.54 | -0.28 | -1.91 | -1.18 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -2.44 | — | — | — | — | — | -999999.00 | -11.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | 0.62 | 2.55 | 6.02 | 9.09 | 0.16 | 0.07 | 0.40 | 2.54 | 1.66 | 3.55 |
| Quick Ratio | 0.51 | 0.51 | 2.43 | 5.91 | 8.97 | 0.13 | 0.06 | 0.33 | 2.26 | 1.48 | 3.40 |
| Cash Ratio | 0.20 | 0.20 | 2.21 | 5.68 | 8.70 | 0.07 | 0.01 | 0.04 | 0.82 | 1.30 | 3.20 |
| Asset Turnover | — | 0.33 | 0.11 | 0.06 | 0.03 | 0.10 | 0.06 | 0.38 | 0.18 | 0.16 | 0.12 |
| Inventory Turnover | 2.14 | 2.14 | 1.27 | 1.17 | 1.26 | 1.54 | 2.80 | 1.72 | 0.56 | 0.67 | 1.31 |
| Days Sales Outstanding | — | 167.59 | 62.26 | 80.30 | 91.00 | 74.87 | 76.81 | 188.72 | 448.71 | 31.12 | 21.35 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $4M | $4M | $3M | $597510 | $143505 | $64080 | $31815 | $14115 | $15615 |
Imminent liquidity exhaustion
According to recent financial data, the company trades at a P/S ratio of 16.49, a valuation that appears increasingly detached from reality given the 99% year-over-year revenue decline and the absence of a clear path to positive earnings or sustainable growth in the near term.
The elevated P/S multiple suggests that the market may still be pricing in a speculative 'AI' premium that is not supported by the company's current transactional revenue base. Investors should monitor whether this valuation reflects a potential liquidation play on the biobank assets rather than a going-concern business model.
As reported in financial statements, the company's gross margin has deteriorated into negative territory at -131%, a stark reversal from the 59.1% margin observed in early 2025, reflecting an inability to cover the direct costs associated with its specialized laboratory and hardware operations.
The collapse in gross margins indicates that the cost of revenue is now exceeding the value of services provided, suggesting that the current operational scale is insufficient to absorb fixed laboratory overhead. This trend warrants further investigation into whether the company's service-based model can ever achieve the economies of scale necessary for profitability.
Based on reported figures, the company's cash conversion cycle has reached extreme negative levels, with DSO figures ballooning to 2624 days in 2025Q3, signaling a profound inability to collect on project-based research services or manage customer credit terms effectively.
The erratic nature of the CCC, coupled with massive DPO spikes, suggests that the company is likely delaying payments to suppliers to preserve its dwindling cash reserves. This operational behavior appears to be a defensive reaction to liquidity constraints rather than a strategic management of working capital.
Data from recent filings indicates that with a current ratio of 0.01 as of 2025Q3, the company faces an existential risk, as its liquid assets are effectively insufficient to cover even a fraction of its immediate short-term liabilities or ongoing operational burn.
The rapid decline in the quick ratio from 4.14 in 2023Q2 to near-zero levels highlights a total exhaustion of the financial cushion that previously supported the company's R&D activities. This liquidity position suggests that the firm is likely dependent on immediate external financing to avoid a cessation of operations.
The most commonly misapplied metric for this business is the P/S ratio, which erroneously treats the company as a scalable software entity, thereby obscuring the reality that its revenue is derived from labor-intensive, project-based laboratory services that lack inherent operating leverage.
Investors should instead focus on the 'cash runway' and 'biobank utilization rate' as more accurate indicators of the company's viability. Applying software-like valuation multiples to a business with negative gross margins and high laboratory overhead creates a valuation trap that ignores the fundamental constraints of the underlying service model.
Includes 30+ ratios · 17 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying POAI stock.
Predictive Oncology Inc.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
Predictive Oncology Inc.'s return on equity (ROE) is -302.4%. The historical average is -232.3%.
Based on historical data, Predictive Oncology Inc. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Predictive Oncology Inc. has 49.1% gross margin and -673.7% operating margin.